These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 36197845)

  • 1. First-in-human study to evaluate safety, tolerability, and immunogenicity of heterologous regimens using the multivalent filovirus vaccines Ad26.Filo and MVA-BN-Filo administered in different sequences and schedules: A randomized, controlled study.
    Bockstal V; Shukarev G; McLean C; Goldstein N; Bart S; Gaddah A; Anumenden D; Stoop JN; Marit de Groot A; Pau MG; Hendriks J; De Rosa SC; Cohen KW; McElrath MJ; Callendret B; Luhn K; Douoguih M; Robinson C
    PLoS One; 2022; 17(10):e0274906. PubMed ID: 36197845
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial.
    Ishola D; Manno D; Afolabi MO; Keshinro B; Bockstal V; Rogers B; Owusu-Kyei K; Serry-Bangura A; Swaray I; Lowe B; Kowuor D; Baiden F; Mooney T; Smout E; Köhn B; Otieno GT; Jusu M; Foster J; Samai M; Deen GF; Larson H; Lees S; Goldstein N; Gallagher KE; Gaddah A; Heerwegh D; Callendret B; Luhn K; Robinson C; Leyssen M; Greenwood B; Douoguih M; Leigh B; Watson-Jones D;
    Lancet Infect Dis; 2022 Jan; 22(1):97-109. PubMed ID: 34529963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial.
    Pollard AJ; Launay O; Lelievre JD; Lacabaratz C; Grande S; Goldstein N; Robinson C; Gaddah A; Bockstal V; Wiedemann A; Leyssen M; Luhn K; Richert L; Bétard C; Gibani MM; Clutterbuck EA; Snape MD; Levy Y; Douoguih M; Thiebaut R;
    Lancet Infect Dis; 2021 Apr; 21(4):493-506. PubMed ID: 33217361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and Immunogenicity of a 2-Dose Heterologous Vaccination Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Uganda and Tanzania.
    Anywaine Z; Whitworth H; Kaleebu P; Praygod G; Shukarev G; Manno D; Kapiga S; Grosskurth H; Kalluvya S; Bockstal V; Anumendem D; Luhn K; Robinson C; Douoguih M; Watson-Jones D
    J Infect Dis; 2019 Jun; 220(1):46-56. PubMed ID: 30796818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: a randomised, double-blind, controlled trial.
    Afolabi MO; Ishola D; Manno D; Keshinro B; Bockstal V; Rogers B; Owusu-Kyei K; Serry-Bangura A; Swaray I; Lowe B; Kowuor D; Baiden F; Mooney T; Smout E; Köhn B; Otieno GT; Jusu M; Foster J; Samai M; Deen GF; Larson H; Lees S; Goldstein N; Gallagher KE; Gaddah A; Heerwegh D; Callendret B; Luhn K; Robinson C; Greenwood B; Leyssen M; Douoguih M; Leigh B; Watson-Jones D;
    Lancet Infect Dis; 2022 Jan; 22(1):110-122. PubMed ID: 34529962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and immunogenicity of an Ad26.ZEBOV booster dose in children previously vaccinated with the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen: an open-label, non-randomised, phase 2 trial.
    Manno D; Bangura A; Baiden F; Kamara AB; Ayieko P; Kallon J; Foster J; Conteh M; Connor NE; Koroma B; Njie Y; Borboh P; Keshinro B; Lawal BJ; Kroma MT; Otieno GT; Deen AT; Choi EM; Balami AD; Gaddah A; McLean C; Luhn K; Adetola HH; Deen GF; Samai M; Lowe B; Robinson C; Leigh B; Greenwood B; Watson-Jones D
    Lancet Infect Dis; 2023 Mar; 23(3):352-360. PubMed ID: 36273490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and Immunogenicity of a 2-Dose Heterologous Vaccine Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Nairobi, Kenya.
    Mutua G; Anzala O; Luhn K; Robinson C; Bockstal V; Anumendem D; Douoguih M
    J Infect Dis; 2019 Jun; 220(1):57-67. PubMed ID: 30796816
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and Immunogenicity of Novel Adenovirus Type 26- and Modified Vaccinia Ankara-Vectored Ebola Vaccines: A Randomized Clinical Trial.
    Milligan ID; Gibani MM; Sewell R; Clutterbuck EA; Campbell D; Plested E; Nuthall E; Voysey M; Silva-Reyes L; McElrath MJ; De Rosa SC; Frahm N; Cohen KW; Shukarev G; Orzabal N; van Duijnhoven W; Truyers C; Bachmayer N; Splinter D; Samy N; Pau MG; Schuitemaker H; Luhn K; Callendret B; Van Hoof J; Douoguih M; Ewer K; Angus B; Pollard AJ; Snape MD
    JAMA; 2016 Apr; 315(15):1610-23. PubMed ID: 27092831
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in healthy and HIV-infected adults: A randomised, placebo-controlled Phase II clinical trial in Africa.
    Barry H; Mutua G; Kibuuka H; Anywaine Z; Sirima SB; Meda N; Anzala O; Eholie S; Bétard C; Richert L; Lacabaratz C; McElrath MJ; De Rosa S; Cohen KW; Shukarev G; Robinson C; Gaddah A; Heerwegh D; Bockstal V; Luhn K; Leyssen M; Douoguih M; Thiébaut R;
    PLoS Med; 2021 Oct; 18(10):e1003813. PubMed ID: 34714820
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in children and adolescents in Africa: A randomised, placebo-controlled, multicentre Phase II clinical trial.
    Anywaine Z; Barry H; Anzala O; Mutua G; Sirima SB; Eholie S; Kibuuka H; Bétard C; Richert L; Lacabaratz C; McElrath MJ; De Rosa SC; Cohen KW; Shukarev G; Katwere M; Robinson C; Gaddah A; Heerwegh D; Bockstal V; Luhn K; Leyssen M; Thiébaut R; Douoguih M;
    PLoS Med; 2022 Jan; 19(1):e1003865. PubMed ID: 35015777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A prophylactic multivalent vaccine against different filovirus species is immunogenic and provides protection from lethal infections with Ebolavirus and Marburgvirus species in non-human primates.
    Callendret B; Vellinga J; Wunderlich K; Rodriguez A; Steigerwald R; Dirmeier U; Cheminay C; Volkmann A; Brasel T; Carrion R; Giavedoni LD; Patterson JL; Mire CE; Geisbert TW; Hooper JW; Weijtens M; Hartkoorn-Pasma J; Custers J; Grazia Pau M; Schuitemaker H; Zahn R
    PLoS One; 2018; 13(2):e0192312. PubMed ID: 29462200
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in infants: a phase 2, randomised, double-blind, active-controlled trial in Guinea and Sierra Leone.
    Choi EM; Lacarra B; Afolabi MO; Ale BM; Baiden F; Bétard C; Foster J; Hamzé B; Schwimmer C; Manno D; D'Ortenzio E; Ishola D; Keita CM; Keshinro B; Njie Y; van Dijck W; Gaddah A; Anumendem D; Lowe B; Vatrinet R; Lawal BJ; Otieno GT; Samai M; Deen GF; Swaray IB; Kamara AB; Kamara MM; Diagne MA; Kowuor D; McLean C; Leigh B; Beavogui AH; Leyssen M; Luhn K; Robinson C; Douoguih M; Greenwood B; Thiébaut R; Watson-Jones D;
    Lancet Glob Health; 2023 Nov; 11(11):e1743-e1752. PubMed ID: 37858585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and Immunogenicity of Heterologous and Homologous 2-Dose Regimens of Adenovirus Serotype 26- and Modified Vaccinia Ankara-Vectored Ebola Vaccines: A Randomized, Controlled Phase 1 Study.
    Goldstein N; Bockstal V; Bart S; Luhn K; Robinson C; Gaddah A; Callendret B; Douoguih M
    J Infect Dis; 2022 Sep; 226(4):595-607. PubMed ID: 32939546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and immunogenicity of an Ad26.ZEBOV booster vaccine in Human Immunodeficiency Virus positive (HIV+) adults previously vaccinated with the Ad26.ZEBOV, MVA-BN-Filo vaccine regimen against Ebola: A single-arm, open-label Phase II clinical trial in Kenya and Uganda.
    Man-Lik Choi E; Abu-Baker Mustapher G; Omosa-Manyonyi G; Foster J; Anywaine Z; Musila Mutua M; Ayieko P; Vudriko T; Ann Mwangi I; Njie Y; Ayoub K; Mundia Muriuki M; Kasonia K; Edward Connor N; Florence N; Manno D; Katwere M; McLean C; Gaddah A; Luhn K; Lowe B; Greenwood B; Robinson C; Anzala O; Kaleebu P; Watson-Jones D;
    Vaccine; 2023 Dec; 41(50):7573-7580. PubMed ID: 37981473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ad26.ZEBOV, MVA-BN-Filo Ebola virus disease vaccine regimen plus Ad26.ZEBOV booster at 1 year versus 2 years in health-care and front-line workers in the Democratic Republic of the Congo: secondary and exploratory outcomes of an open-label, randomised, phase 2 trial.
    Larivière Y; Matuvanga TZ; Osang'ir BI; Milolo S; Meta R; Kimbulu P; Robinson C; Katwere M; McLean C; Lemey G; Matangila J; Maketa V; Mitashi P; Van Geertruyden JP; Van Damme P; Muhindo-Mavoko H
    Lancet Infect Dis; 2024 Jul; 24(7):746-759. PubMed ID: 38552653
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lot-to-lot consistency, immunogenicity, and safety of the Ad26.ZEBOV, MVA-BN-Filo Ebola virus vaccine regimen: A phase 3, randomized, double-blind, placebo-controlled trial.
    Goldstein N; McLean C; Gaddah A; Doua J; Keshinro B; Bus-Jacobs L; Hendriks J; Luhn K; Robinson C; Douoguih M
    Hum Vaccin Immunother; 2024 Dec; 20(1):2327747. PubMed ID: 38523332
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant Protein Filovirus Vaccines Protect Cynomolgus Macaques From Ebola, Sudan, and Marburg Viruses.
    Lehrer AT; Chuang E; Namekar M; Williams CA; Wong TAS; Lieberman MM; Granados A; Misamore J; Yalley-Ogunro J; Andersen H; Geisbert JB; Agans KN; Cross RW; Geisbert TW
    Front Immunol; 2021; 12():703986. PubMed ID: 34484200
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and Immunogenicity of the Heterologous 2-Dose Ad26.ZEBOV, MVA-BN-Filo Vaccine Regimen in Health Care Providers and Frontliners of the Democratic Republic of the Congo.
    Larivière Y; Garcia-Fogeda I; Zola Matuvanga T; Isekah Osang'ir B; Milolo S; Meta R; Kimbulu P; Robinson C; Katwere M; McLean C; Hens N; Matangila J; Maketa V; Mitashi P; Muhindo-Mavoko H; Van Geertruyden JP; Van Damme P
    J Infect Dis; 2024 Apr; 229(4):1068-1076. PubMed ID: 37673423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distinct Immunogenicity and Efficacy of Poxvirus-Based Vaccine Candidates against Ebola Virus Expressing GP and VP40 Proteins.
    Lázaro-Frías A; Gómez-Medina S; Sánchez-Sampedro L; Ljungberg K; Ustav M; Liljeström P; Muñoz-Fontela C; Esteban M; García-Arriaza J
    J Virol; 2018 Jun; 92(11):. PubMed ID: 29514907
    [No Abstract]   [Full Text] [Related]  

  • 20. Monitoring of Adverse Events in Recipients of the 2-Dose Ebola Vaccine Regimen of Ad26.ZEBOV Followed by MVA-BN-Filo in the UMURINZI Ebola Vaccination Campaign.
    Nyombayire J; Ingabire R; Magod B; Mazzei A; Mazarati JB; Noben J; Katwere M; Parker R; Nsanzimana S; Wall KM; Sayinzoga F; Tichacek A; Robinson C; Hammoud N; Priddy F; Allen S; Karita E
    J Infect Dis; 2023 Jan; 227(2):268-277. PubMed ID: 35776140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.